PDCD1 and melanoma: Another neoantigen-based vaccine, NEO-PV-01, combined with or without anti-PD-1 antibody in an Ib clinical trial of 60 patients who received the vaccine, ORR was 59% (39%-78%), 39% (17%-64%), and 27% (8%-55%) in melanoma, non-small cell lung cancer (NSCLC), and bladder cancer patients, respectively.